An improved treatment option - Age‐adapted, easy‐to‐use, affordable, and non‐patented tablet, for the treatment of Chagas
- disease in infants and young children under 2 years of age (20 kg body weight).
- Contributes to improved dosing accuracy, safety, and adherence to treatment
- Granted registration by Brazil’s National Health Surveillance Agency (ANVISA), with further endemic countries targeted for obtaining registration.
|
Main advantages of the Paediatric dosage form of Benznidazole
- A single tablet allows coverage of a wide age range, up to 2 years old or body weight 20 kg
- Child‐adapted dose of 12.5 mg per tablet
- Easily dispersible tablet to facilitate oral administration
- No need for tablet fractionation (except for low‐birth weight babies <2.5 kg: half a tablet)
- Simple and reliable administration that does not require complex preparation and can therefore be administered at home, even during the long duration of treatment (twice daily for 60 days)
|
A collaborative partnership | Result of a three‐year collaborative partnership, starting in 2008, between DNDi and the Pernambuco State Pharmaceutical Laboratory (Laboratório Farmacêutico do Estado de Pernambuco; LAFEPE) of Brazil. LAFEPE is the second largest public laboratory in Brazil and the only producer of benznidazole in the world.
|
Download Paediatric Benznidazole dossier (12/2011) [PDF]
| |
|
Paediatric Benznidazole
